ArticleOncology letters2025
Signature of immune infiltration-related ferroptosis genes to predict the prognosis of patients with osteosarcoma.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is the most prevalent malignant bone tumor among children and adolescents, and ferroptosis has been implicated in tumor immune infiltration. The present study aimed to explore the role of ferroptosis-related genes in immune infiltration and to develop a prognostic signature for osteosarcoma (OS). In the present study, two immune subtypes of OS were identified and demonstrated to be reproducible and effective. Building upon the distinction between high and low immunity, six common differentially expressed immune infiltration-related ferroptosis genes (DEIIRFGs) were identified. After which, univariate Cox regression (UCR) analysis was employed to identify DEIIRFGs associated with overall survival. Next, using Gene Ontology analysis, it was revealed that the six mRNAs were enriched in the immune-associated functions and pathway. Subsequently, using UCR analysis and the iterative Least Absolute Shrinkage and Selection Operator Cox regression analysis based on two ferroptosis genes (interferon-γ and toll-like receptor 4), a model was established. Additionally, it was confirmed that the risk model was an independent prognostic factor for overall survival. Furthermore, the results were verified using a Gene Expression Omnibus dataset. Finally, the content of tumor-infiltrating immune cells demonstrated that the high-risk group was significantly associated with immune cell infiltration, compared with the low-risk group. Moreover, the expression of immune checkpoint inhibitors was significantly upregulated in the low-risk cohort compared with in the high-risk cohort. Finally, using gene set enrichment analysis, it was demonstrated that the risk score was associated with the toll-like receptor signaling pathway, antigen processing and presentation, and cytokine-cytokine receptor interaction. In summary, a signature of DEIIRFGs to predict prognosis in patients with OS was developed. Moreover, it was demonstrated that the molecular mechanisms responsible in the high-risk group may influence immune infiltration-related biological processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.